title: Systematic analysis of overall survival and interactions between tumor mutations and drug treatment.
abstract: BACKGROUND
  Few exceptional responses in cancer treatment were attributed to a genetic predisposition of the tumor.
  
  
  METHODS
  We analyzed a cohort of 3105 patients from 12 different cancer types and systematically sought the existence of a correlation between overall survival and the interaction of 21 antineoplastic treatments with 6 tumor mutations.
  
  
  RESULTS
  We identified a single significant correlation resulting in increased overall survival from temozolomide in lower-grade glioma with IDH1 R132H mutations. The trend could not be attributed to either the treatment or the mutation alone. Univariate and multivariate Cox regression demonstrated that this interaction stood as an independent prognostic predictor of survival.
  
  
  CONCLUSIONS
  Our results suggest infrequent instances of exceptional responses ascribable to tumor genomics yet corroborate the existence of an interaction of temozolomide with IDH1 mutations in lower-grade glioma.
authors.affiliation: Department of Biology and Biological Engineering, Chalmers University of Technology, Göteborg, 41296, Sweden.
authors.forename: Francesco
authors.initials: F
authors.lastname: Gatto
authors.affiliation: Department of Biology and Biological Engineering, Chalmers University of Technology, Göteborg, 41296, Sweden. nielsenj@chalmers.se.
authors.forename: Jens
authors.initials: J
authors.lastname: Nielsen
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics; D053208:Kaplan-Meier Estimate; D015999:Multivariate Analysis; D020125:Mutation, Missense; D060787:Neoplasm Grading; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011379:Prognosis; D016016:Proportional Hazards Models; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human; D000077204:Temozolomide